source
- Denali Therapeutics' Avlayah generates $3.6M in Q1, beating forecastsDenali Therapeutics reported that its newly launched Hunter syndrome therapy Avlayah earned $3.6 million in revenue during the first quarter after its April market entry. Analysts had projected ro…
- Replimune secures FDA approval for Tudriqev, eyes $1.3 bn peak sales in advanced melanomaReplimune announced FDA approval of its therapy Tudriqev for patients with advanced melanoma who have progressed after PD-1 treatment. Analysts at BMO Capital Markets project the drug could genera…